Form 4: Amicus Therapeutics Acquired by BioMarin

Chief People Officer David Michael Clark reports the disposal of all equity holdings following the acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.

Summary

• David Michael Clark, Chief People Officer of Amicus Therapeutics, disposed of 221,811 shares of common stock at $14.50 per share.
• Multiple tranches of stock options were cancelled and converted into cash payments based on the $14.50 acquisition price per share.
• The transactions were executed on April 27, 2026, in connection with the completed merger with BioMarin Pharmaceutical Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a standard administrative filing confirming the final exit of an executive following a completed corporate acquisition.

Positives

• The acquisition by BioMarin provides liquidity to shareholders and executives at a fixed price of $14.50 per share.

Negatives

• The company ceases to exist as an independent publicly traded entity following the merger.

Risks

• No ongoing risks as the company has been acquired.

Future Outlook

The company has been acquired by BioMarin Pharmaceutical Inc., and no further independent guidance is provided.

Management Comments

• The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc.

Industry Context

StockSavvy.ai notes that this acquisition represents a consolidation in the rare disease and biotechnology sector, where larger pharmaceutical entities are increasingly acquiring specialized firms to bolster their pipelines.

Comparison to Industry Standards

• The acquisition price of $14.50 reflects the final valuation agreed upon by the boards of Amicus and BioMarin.
• The conversion of unvested options into cash upon a change-in-control event is standard practice in biotechnology M&A transactions.

Stakeholder Impact

• Shareholders receive cash consideration for their holdings.
• Employees and executives transition to the acquiring entity or depart.

Next Steps

• Delisting of Amicus Therapeutics (FOLD) from the stock exchange.

Key Dates

Keywords

Amicus Therapeutics, BioMarin, Merger, Acquisition, FOLD, Form 4, Insider Transaction